Nordic Nanovector: European Patent Granted for Betalutin® or Humalutin® in Combination With Anti-CD20 Antibodies for Treating NHL

Corporate Breaking News

Home : Nordic Nanovector: European Patent Granted for Betalutin® or Humalutin® in Combination With Anti-CD20 Antibodies for Treating NHL

Jun 03 2019	Nordic Nanovector: European Patent Granted for Betalutin® or Humalutin® in Combination With Anti-CD20 Antibodies for Treating NHL
OSLO, Norway, June 3, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the European Patent Organisation (EPO) has granted the company's European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of...


Source:https://www.prnewswire.com:443/news-releases/nordic-nanovector-european-patent-granted-for-betalutin-or-humalutin-in-combination-with-anti-cd20-antibodies-for-treating-nhl-300860386.html

Related News
» Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials » Argus launches IMO 2020-compliant assessments for Zhoushan, China